JAK inhibitors (JAKi) are new targeted-synthetic drugs, approved for various immune-
mediated inflammatory diseases (IMIDs), including inflammatory arthritides (rheumatoid …

Abstract Background Janus kinase inhibitors (JAKis) is a new therapeutic class in
autoimmune and inflammatory diseases. Four molecules are approved in rheumatoid …

Background: Tofacitinib (TOFA) was the first Janus kinase inhibitor (JAKi) to be approved for
the treatment of rheumatoid arthritis (RA). However, data on the retention rate of TOFA …

The drug retention rate has been an important indicator for evaluating the treatment
tolerance. Unfortunately, our knowledge of the secukinumab retention rate in radiographic …

Tofacitinib was the first Janus kinase inhibitor to be approved for the treatment of rheumatoid
arthritis (RA), and there is a large body of data to inform the efficacy and safety of this drug …

Objective Janus kinase inhibitors are expected to change the management patterns and
prognosis of chronic rheumatic diseases. This study aimed to evaluate the efficacy, drug …

Tofacitinib is an oral Janus kinase (JAK) inhibitor indicated for the treatment of rheumatoid
arthritis (RA). The efficacy and safety/tolerability of tofacitinib have been extensively …

Objectives The persistence in therapy of rheumatoid arthritis drugs and particularly
bDMARD is a limiting factor for their long-term use. The randomized controlled trials (RCTs) …

Introduction Obese rheumatoid arthritis (RA) patients often show reduced responses to
traditional treatments, including TNF inhibitors (TNFi). Considering the different mechanisms …

Background Rheumatoid arthritis is a progressive disease that requires continuous
treatment. Despite the excellent results, treatment with biologics and target-specific disease …